Nanoscope Therapeutics announced that its optogenetics gene therapy (Mogenry, MCO-010) will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) 2026 annual meeting taking place October 8–13, 2026, in New Orleans. Additionally, the company will participate in Eyecelerator@AAO 2026 with a company presentation and panel participation. 

Presentation Details:

Eyecelerator 2026, Ernest N. Morial Convention Center

Panel: Emerging Innovations in Retinal Therapies

Panelist: Sam Barone, MD, Chief Medical Officer

Date & Time: Thursday, October 8, 2026, 10:45–11:30 AM CT

Location: La Nouvelle Ballroom C

Company Presentation: Retina Drug Delivery & New Targets Showcase

Presenter: Paul Hallen, Chief Operating Officer

Date & Time: Thursday, October 8, 2026, 1:00–1:05 PM CT

Location: Rooms 252–254

AAO 2026 Annual Meeting, Ernest N. Morial Convention Center

Presentation: Lasting Vision Improvement in Retinitis Pigmentosa: REMAIN 4-Year Study Data From the RESTORE Phase 2b/3 Trial of MCO-010 Optogenetic Therapy

Session: PA044

Presenter: Kenneth C. Fan, MD

Date & Time: Sunday, October 11, 2026, 11:42–11:49 AM CT

Location: Rooms 255–257

Scientific Poster: Vision Improvement in Dry AMD With Sonpiretigene Isteparvovec Optogenetic Therapy: First Direct-to-Phase 2 RCT

Session: PO624

Presenter: David S. Boyer, MD

Availability: On demand